Circulating Steroid Hormones and the Risk of Prostate Cancer
Open Access
- 1 January 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 15 (1) , 86-91
Abstract
Epidemiologic studies have failed to support the hypothesis that circulating androgens are positively associated with prostate cancer risk and some recent studies have even suggested that high testosterone levels might be protective particularly against aggressive cancer. We tested this hypothesis by measuring total testosterone, androstanediol glucuronide, androstenedione, DHEA sulfate, estradiol, and sex hormone–binding globulin in plasma collected at baseline in a prospective cohort study of 17,049 men. We used a case-cohort design, including 524 cases diagnosed during a mean 8.7 years follow-up and a randomly sampled subcohort of 1,859 men. The association between each hormone level and prostate cancer risk was tested using Cox models adjusted for country of birth. The risk of prostate cancer was ∼30% lower for a doubling of the concentration of estradiol but the evidence was weak (Ptrend = 0.07). None of the other hormones was associated with overall prostate cancer (Ptrend ≥ 0.3). None of the hormones was associated with nonaggressive prostate cancer (all Ptrend ≥ 0.2). The hazard ratio [HR; 95% confidence interval (95% CI)] for aggressive cancer almost halved for a doubling of the concentration of testosterone (HR, 0.55; 95% CI, 0.32-0.95) and androstenedione (HR, 0.51; 95% CI, 0.31-0.83), and was 37% lower for a doubling of the concentration of DHEA sulfate (HR, 0.63; 95% CI, 0.46-0.87). Similar negative but nonsignificant linear trends in risk for aggressive cancer were obtained for free testosterone, estradiol, and sex hormone–binding globulin (Ptrend = 0.06, 0.2, and 0.1, respectively). High levels of testosterone and adrenal androgens are thus associated with reduced risk of aggressive prostate cancer but not with nonaggressive disease. (Cancer Epidemiol Biomarkers Prev 2006;15(1):86–91)Keywords
This publication has 19 references indexed in Scilit:
- Sex Steroid Hormones and the Androgen Receptor Gene CAG Repeat and Subsequent Risk of Prostate Cancer in the Prostate-Specific Antigen EraCancer Epidemiology, Biomarkers & Prevention, 2005
- Long-Term Survival Rates of Patients With Prostate Cancer in the Prostate-Specific Antigen Screening Era: Population-Based Estimates for the Year 2000 by Period AnalysisJournal of Clinical Oncology, 2005
- The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancerThe Journal of Steroid Biochemistry and Molecular Biology, 2004
- High levels of circulating testosterone are not associated with increased prostate cancer risk: A pooled prospective studyInternational Journal of Cancer, 2003
- The Influence of Finasteride on the Development of Prostate CancerNew England Journal of Medicine, 2003
- Hormones and Prostate Cancer: What's Next?Epidemiologic Reviews, 2001
- Time-to-Event Analysis of Longitudinal Follow-up of a Survey: Choice of the Time-scaleAmerican Journal of Epidemiology, 1997
- Prospective Study of Sex Hormone Levels and Risk of Prostate CancerJNCI: Journal of the National Cancer Institute, 1996
- A case-cohort design for epidemiologic cohort studies and disease prevention trialsBiometrika, 1986
- Calculation of free and bound fractions of testosterone and estradiol-17β to human plasma proteins at body temperatureThe Journal of Steroid Biochemistry and Molecular Biology, 1982